Should I buy or sell Ventyx Biosciences stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VTYX shares. View VTYX analyst ratings or view top-rated stocks .

What is Ventyx Biosciences' stock price target for 2024?

9 brokers have issued 12-month price objectives for Ventyx Biosciences' shares. Their VTYX share price targets range from $5.00 to $62.00. On average, they anticipate the company's share price to reach $21.75 in the next year. This suggests a possible upside of 396.6% from the stock's current price. View analysts price targets for VTYX or view top-rated stocks among Wall Street analysts .

How have VTYX shares performed in 2024?

Ventyx Biosciences' stock was trading at $2.47 at the beginning of the year. Since then, VTYX shares have increased by 77.3% and is now trading at $4.38. View the best growth stocks for 2024 here .

When is Ventyx Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VTYX earnings forecast .

How were Ventyx Biosciences' earnings last quarter?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) issued its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.08. During the same quarter last year, the business posted ($0.62) EPS.

What ETFs hold Ventyx Biosciences' stock?

ETFs with the largest weight of Ventyx Biosciences (NASDAQ:VTYX) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY) . iShares U.S. Pharmaceuticals ETF (IHE) .

When did Ventyx Biosciences IPO?

Ventyx Biosciences (VTYX) raised $152 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 9,472,656 shares at $15.00-$17.00 per share.

How do I buy shares of Ventyx Biosciences?

Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VTYX

Ventyx Biosciences (VTYX) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free VTYX Stock Alerts

$4.47

+0.12 (+2.76%)

(As of 04:00 PM ET)

Compare

Today's Range: $4.26
▼
$4.63
50-Day Range: $2.29
▼
$10.13
52-Week Range: $1.87
▼
$40.58

Volume: 906,002 shs
Average Volume: 3.79 million shs
Market Capitalization: $315.14 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.75

Get Ventyx Biosciences alerts:

Ventyx Biosciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.56 Rating Score
Upside/Downside: 396.6% Upside
$21.75 Price Target
Short Interest: Healthy
19.58% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.05
Based on 11 Articles This Week
Insider Trading: Selling Shares
$39,787 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.55) to ($2.47) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.66 out of 5 stars

Medical Sector

420th out of 918 stocks

Pharmaceutical Preparations Industry

186th out of 419 stocks

3.3

Analyst's Opinion

Consensus Rating
Ventyx Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Ventyx Biosciences has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
19.58% of the float of Ventyx Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Ventyx Biosciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Ventyx Biosciences has recently decreased by 2.43%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Ventyx Biosciences does not currently pay a dividend.
Dividend Growth
Ventyx Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VTYX.

1.7

News and Social Media Coverage

News Sentiment
Ventyx Biosciences has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Ventyx Biosciences this week, compared to 4 articles on an average week.
Search Interest
Only 4 people have searched for VTYX on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Ventyx Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -82% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ventyx Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,787.00 in company stock.
Percentage Held by Insiders
24.39% of the stock of Ventyx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.88% of the stock of Ventyx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ventyx Biosciences are expected to grow in the coming year, from ($2.55) to ($2.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ventyx Biosciences is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ventyx Biosciences is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ventyx Biosciences has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Ventyx Biosciences Stock (NASDAQ:VTYX)

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

VTYX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VTYX Stock News Headlines

April 4, 2024 | insidertrades.com

Raju Mohan Sells 4,312 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock

April 19, 2024 | markets.businessinsider.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx Biosciences

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 19, 2024 | prnewswire.com

Ventyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 30, 2024 to Discuss Your Rights - VTYX

April 18, 2024 | msn.com

Big Pharma Targets Weight-Loss Drug Firms for Buyouts: Here are 4 Potential Candidates

April 17, 2024 | markets.businessinsider.com

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx Biosciences

April 17, 2024 | markets.businessinsider.com

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

April 16, 2024 | prnewswire.com

VTYX Investors Have Opportunity to Lead Ventyx Biosciences, Inc. Securities Fraud Lawsuit

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 16, 2024 | prnewswire.com

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYX

April 15, 2024 | markets.businessinsider.com

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

April 15, 2024 | prnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYX

April 14, 2024 | prnewswire.com

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTYX

April 13, 2024 | prnewswire.com

INVESTOR INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx Biosciences

April 12, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTYX

April 12, 2024 | prnewswire.com

The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX

April 11, 2024 | markets.businessinsider.com

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

April 11, 2024 | americanbankingnews.com

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of "Moderate Buy" from Analysts

April 10, 2024 | markets.businessinsider.com

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

April 10, 2024 | msn.com

Ventyx Biosciences drops 3%, stockholders to sell ~11.17M shares

April 10, 2024 | prnewswire.com

Levi & Korsinsky Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX

April 9, 2024 | prnewswire.com

VTYX Investors Have Opportunity to Lead Ventyx Biosciences, Inc. Securities Fraud Lawsuit

April 9, 2024 | prnewswire.com

Investors in Ventyx Biosciences, Inc. Should Contact The Gross Law Firm Before April 30, 2024 to Discuss Your Rights - VTYX

April 8, 2024 | markets.businessinsider.com

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx

April 8, 2024 | markets.businessinsider.com

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

April 8, 2024 | prnewswire.com

April 30, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTYX

April 7, 2024 | prnewswire.com

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTYX

See More Headlines

Receive VTYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VTYX
CUSIP: N/A
CIK: 1851194
Web: www.ventyxbio.com
Phone: 760-593-4832
Fax: N/A
Employees: 79
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.75
High Stock Price Target: $62.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +387.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.56
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-192,960,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -62.58%
Return on Assets: -57.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.87
Quick Ratio: 11.87

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.13 per share
Price / Book: 1.08

Miscellaneous

Outstanding Shares: 70,500,000
Free Float: 53,304,000
Market Cap: $314.43 million
Optionable: Optionable
Beta: 0.27

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Sheila K. Gujrathi M.D. (Age 54)
Executive Chairperson
Comp: $125k
Dr. John M. Nuss Ph.D. (Age 65)
Chief Scientific Officer
Comp: $656.99k
Dr. Martin Douglas Auster M.D. (Age 49)
Chief Financial Officer
Mr. Christopher W. Krueger J.D. (Age 56)
MBA, Chief Business Officer
Comp: $568.14k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VTYX Stock Analysis - Frequently Asked Questions

Should I buy or sell Ventyx Biosciences stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VTYX shares.
View VTYX analyst ratings or view top-rated stocks.
What is Ventyx Biosciences' stock price target for 2024?: 9 brokers have issued 12-month price objectives for Ventyx Biosciences' shares. Their VTYX share price targets range from $5.00 to $62.00. On average, they anticipate the company's share price to reach $21.75 in the next year. This suggests a possible upside of 396.6% from the stock's current price.
View analysts price targets for VTYX or view top-rated stocks among Wall Street analysts.
How have VTYX shares performed in 2024?: Ventyx Biosciences' stock was trading at $2.47 at the beginning of the year. Since then, VTYX shares have increased by 77.3% and is now trading at $4.38.
View the best growth stocks for 2024 here.
When is Ventyx Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VTYX earnings forecast.

How were Ventyx Biosciences' earnings last quarter?: Ventyx Biosciences, Inc. (NASDAQ:VTYX) issued its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.08. During the same quarter last year, the business posted ($0.62) EPS.
What ETFs hold Ventyx Biosciences' stock?: ETFs with the largest weight of Ventyx Biosciences (NASDAQ:VTYX) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).iShares U.S. Pharmaceuticals ETF (IHE).
When did Ventyx Biosciences IPO?: Ventyx Biosciences (VTYX) raised $152 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 9,472,656 shares at $15.00-$17.00 per share.
How do I buy shares of Ventyx Biosciences?: Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VTYX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ventyx Biosciences (VTYX) Stock Price, News & Analysis

Ventyx Biosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Ventyx Biosciences Stock (NASDAQ:VTYX)

VTYX Stock Price History

VTYX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VTYX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™